Adolor Corporation (Nasdaq: ADLR) is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The company announced GlaxoSmithKline (GSK) returned to Adolor the worldwide rights related to Entereg for chronic opioid bowel dysfunction (OBD), as well as rights related to Entereg for irritable bowel syndrome (IBS).

While GSK will retain the rights to Entereg in regards to postoperative ileus (POI), Adolor will work with GSK to coordinate development and commercialization of Entereg for POI in the United States.

OBD is commonly described as constipation, but also includes other gastrointestinal effects such as abdominal cramping, bloating and gastroesophageal reflux. According to Michael R. Dougherty, president and CEO of Adolor, the company intends on addressing the needs for individuals affected by OBD.

“There is a large, unmet need for treatment options for the many patients who suffer with chronic OBD,” Dougherty stated in the